Member Info for BOJO2020

Can’t get my limit buy filled. Do we know anyone that is desperate to sell??

Thought not!

1509,

Just and idea.

Why not pick two stocks for quick comp and the joker/wild card could be the long term play.

I see that Inan and Bunsie have it covered :-)

PHE are not sure how this new variant may react to the current vaccines. 3 cases on Scotland and 3 in England of which 1 person has eluded detection in England. All according to Channel 4 news.

If only there was a vaccines that could attack the N protein...

Sorry if this has already been raised/discussed I am watching channel 4 plus 1!

Can I have

Angle 82p
SCLP 23p

Joker

ECR 3.68p

Many Thanks

Well Done Brazil, Eva & co plus Nolupus

We simply do not have enough information available at this stage regarding the trial and potential partners, but we clearly won’t have to wait too long.

Understandably we will have a tendency to guess in such circumstances but for me we have 3 or maybe 4 shots on goal this year.

It comes down to the same old thing: patience.

Don’t expect people whether they be investors, customers or politicians to join up the dots. For any business to be successful, people need to have things handed to them on a plate. Not only that but they need everything sliced up into digestible chunks.

The whys and wherefore’s look like obstacles to the unaware and so they always take the route of least resistance!

Investors are off chasing CBX or what ever the latest thing is. Me and you will collect IES and BMN shares until the penny drops...

To add to my earlier post 7.12. Put time into the equation. Is a deal nearly done or in the pipeline or maybe not at all?

After a sleepless night I have decided to hold all shares and add on news. Important to have my own strategy straight here and stick to it.

ATB.

Regarding COVIDITY, as long as phase 1 data sets and efficacy proven by phase 2. If you were a major Pharma without a stronger candidate to combat Covid then you would take on COVIDITY surely.

To be fair Imm are a special case.

DNL had no trouble with FDA & Angle will more than likely not face any type of serious delay. Yes the FDA site that there may be delays but Imm took that another level.

Just my opinion but we should all note the name Tim McCarthy as un-investmentable!

I think the point of the presentation was to set the course for the future starting this year. For a new investor it would have certainly done this IMO. For current holders we have heard much of it before so will have had less impact.

On balance I was happy with the presentation as it it started us off on the right foot. Those that are not on board with this idea will fall into line when the RNS news begins to flow.

ATB.

Profd

I was in Curzon about 8 months ago. The BB members were all underwater and lied about where the company was going. I presume they still hold shares.

Unless it is under new management with a very good track record, I’d say don’t touch.

DNL @ SNG?

1509,

Can’t predict the future but I am hoping for 35p and that will come with RNS concerning production, dosage, trial starting. Hopefully any or all of these will drive price.

Scancell holders have very sticky hands. What does that mean? They sell high and buy low and therefore accumulate a lot of shares!!

That results in a growing share price that builds steadily and does not retrace for long as the dips are bought. Remember Redmile own 29% and they are not selling as cash invested is funding trials $40mill.

BionTech collaboration continues on Modi1 which looks very promising. BionTech and Scancell love them T Cells!

Data sets from COVIDITY available this year (phase 1 ) followed by a phase 2 possibly this year to prove efficacy. Then a major takes over Covid program. Do they have one lined up? Who knows but if the data sets are better than a big pharma’s own then it would be likely IMO.

So 3 clinical trials due to start this year :

2 cancer and 1 COV 19 (possibly a 4th if phase 2 COVIDITY).

Personally, I don’t like paying pounds for shares so I accumulate at low levels or trade the hell out of the expensive ones.

Watch the presentation on Vox markets.

ATB.

Following SKY News articles (TV & Website) New York Post, all major Sunday newspapers coverage. Scancell are presenting on VOX Markets with Turner Pope.

Link does not work but you can search Vox markets on Twitter.

5.30pm GMT

ATB

Riki & scored

I would hope the people that the company read this board. They have a Twitter feed that I am following and I can tell you there are three tweets in since November 2020.

Let’s be clear, DNL are NOT engaging with people on that platform. It isn’t necessary to set a huge budget and appoint a marketing company, develop a profile and have endless meetings to communicate with people. Just say hi or interact with the world so that people know DNL has views...That it exists and what it stands for!

Interact with other scientist...

A congrats to Pfizer BionTech or AZ Oxford maybe?

A Good luck to Nottingham University’s with their vaccine research. Or Southampton University Hospital on its many COVID initiatives.

Like Mars Rover for landing! Show the world that DNL is interested in the world/science or something.

It appears to me that the company is very focused but looking inwards. Problem with that is how are people ever going to know about them unless they just stumble across them like I did.

I have been in business for ever and whilst I cringe at the thought of networking it is necessary or at the very least work hard on the marketing.

I am not worried about the SP or that the company will fail to achieve its goals.

They are however missing a very simple, effective and inexpensive route to market. More fool them I say

DIG,

Try Vox Markets - Scancell

Any chance Diurnal can use its Twitter account more regularly please!!!

It is all very well doing deals on the back ground and announcing them with an occasional wow, but making people aware of the Company isn’t a bad idea IMO.

The Company has plenty of things to be proud of and that people would be interested in.

Such people may be:

Institutions
Scientists
Patients
Investors
Doctors

You get the gist...

Just my opinion.

The company would surely have spoken to nomad so all information will be non price sensitive one would imagine.

Bought more HZM which is getting ever closer to placing price.

Used other profits to buy into IES for the first time @ £1.63. Hoping it bounces back to £2 to £2.20 range.

Thought seriously about Rdgc but can’t get my head around it as I like to ponder! Anyhow very best of luck those that are more decisive and have taken the plunge!

I am getting used to watching you all making money from the sidelines lol.

ATB